These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1112 related items for PubMed ID: 15545527

  • 1. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 16; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 16; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 4. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 16; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 5. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M, Ménard J.
    Circulation; 2004 Jun 01; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB, Stark JE.
    Pharmacotherapy; 2008 Jul 01; 28(7):920-31. PubMed ID: 18576907
    [Abstract] [Full Text] [Related]

  • 7. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Jul 01; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 01; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 9. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S, Kitakaze M.
    Nihon Rinsho; 2003 May 01; 61(5):821-6. PubMed ID: 12755009
    [Abstract] [Full Text] [Related]

  • 10. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E, Andrés A, Polanco N, Toribio MJ, Santana R, Gutiérrez Martínez E, González J, Ramírez E, Hernández A, Morales E, Praga M, Morales JM.
    Transplant Proc; 2010 Oct 01; 42(8):2899-901. PubMed ID: 20970564
    [Abstract] [Full Text] [Related]

  • 11. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 01; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 12. [Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure].
    Aoyama N.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():145-9. PubMed ID: 17569312
    [No Abstract] [Full Text] [Related]

  • 13. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G.
    Nephrol Ther; 2010 Jan 28; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract] [Full Text] [Related]

  • 14. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May 28; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

  • 15. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 May 28; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 16. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 28; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 28; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 18. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 28; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 19. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 28; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

  • 20. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Apr 28; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.